Farmacy

Feb 19 2018

Global ETF List: Complete List from, pharma etf.#Pharma #etf

Global ETF List Global ETF List ETFs within this category: Information on this website should not be considered to be investment advice. Any ETF can go DOWN as well as up. Information on this website should not be assumed to be complete or correct. Funds can also change their investment goals. That’s why, wherever possible, we provide links to the actual fund sponsor and the exchange on which the fund trades.

Feb 19 2018

Biotech Stocks To Watch And Pharma Industry News, Stock News – Stock Market Analysis, pharma

Technology Visit the IBD Store to get started. Technology Biotech Stocks To Watch And Pharma Industry News IBD STAFF 11/10/2017 One minute Dow Jones industrial average component Merck (MRK) might be doing battle with fellow drugmaker Bristol-Myers Squibb (BMY) over drugs that can ward off cancer. The next, biotech giants like Amgen (AMGN) and Sanofi (SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences (GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis. It’s a brave – and contentious – new world for pharmaceutical …

Feb 19 2018

Protea Biopharma, bio pharma.#Bio #pharma

About Protea Biopharma PROTEA biopharma N.V. is a Belgian biopharma company developing improved diagnostics and therapeutics for infectious and chronic immune diseases that affect millions of people worldwide. History and activities PROTEA biopharma’s activities started in 1998, with the acquisition of a license from Temple University, USA. This license granted to the Company the exclusive rights to commercialize a new marker for chronic fatigue syndrome (CFS-ME), based on the detection of an abnormal form of Ribonuclease L, an enzyme involved in antiviral defense. In 1999 the Company raised 3.3 million euro in equity investment and recruited a multidisciplinary team of …

Feb 19 2018

Biotech Industry, Biotech News, Biotechnology Articles, bio pharma.#Bio #pharma

bio pharma Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms. Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing. Cytokinetics cans lead drug after phase 3 ALS wipeout Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial. Step Pharma bags cash for CTPS1 autoimmune R D drive …

Feb 19 2018

Top 10 Pharmaceutical Companies in India, Top Pharma Company in India, top 10 pharma.#Top #10

Top 10 Pharmaceutical Companies in India In the list of top pharmaceutical companies in India it is not the Indian companies but also the MNCs that are becoming the part of the race. Indian pharmaceutical market in 2008 was $7,743m and if compared to year 2007 it was 4% more than that. It is expected that Indian pharmaceutical market will grow more than the global pharmaceutical market and will become $15,490 million in 2014. Today Indian pharmaceutical industry is the second most fastest growing industry displaying the revenue of Rs 25,196.48 crore and growth of 27.32 percent. Top pharmaceutical companies …

Feb 19 2018

It – s Merck vs, merck pharma.#Merck #pharma

It s Merck vs. Merck as name confusion, complicated by social media, leads to legal showdown Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle between Germany s Merck KGaA and U.S.-based Merck Co. ($MRK), known as MSD outside the U.S. The companies are engaged in a multicountry legal fight over the misunderstandings that come from sharing the same name for 125 years. The eruption comes over the use of the shared moniker by Merck Co., in online …

Feb 19 2018

Bio Pharma Giant – Celgene – Settles Case Alleging Marketing Violations For $280 Million, bio

Bio Pharma Giant — Celgene — Settles Case Alleging Marketing Violations For $280 Million News provided by Jul 25, 2017, 17:08 ET Share this article LOS ANGELES , July 25, 2017 /PRNewswire-USNewswire/ — On the eve of trial, Bio Pharma giant, Celgene Corporation, has agreed to pay $280 million to resolve allegations it sold and promoted its blockbuster drugs, Thalomid and Revlimid, in violation of federal and state laws. The case, U.S. ex rel. Brown v. Celgene, CV 10-03165 (RK) ( C.D. Cal .), was brought by a former Celgene sales representative, Beverly Brown , under the federal False Claims …

Feb 19 2018

Ibuprofen – Actavis, actavis pharma.#Actavis #pharma

Ibuprofen “Actavis” Ibuprofen “Actavis” er et middel mod gigt og smerter. NSAID. Virksomme stoffer Anvendelse Ibuprofen “Actavis” anvendes til behandling af svage smerter, fx hovedpine, tandpine, muskel- og ledsmerter eller menstruationssmerter. Midlet dæmper desuden de vævsreaktioner (inflammation), som kan ses ved visse gigtsygdomme, eller som kan opstå efter et slag eller en forstuvning. Symptomerne på inflammation kan være hævelse, rødme, ømhed og smerter. Dosering Findes som tabletter. Voksne. Sædvanligvis 200-400 mg efter behov, højst 3 gange i døgnet. Sædvanligvis 400 mg. Dosis gentages evt. med 6-8 timers mellemrum. Voksne. Sædvanligvis 1200-1800 mg i døgnet fordelt på 3-4 doser. Dosis kan …

Feb 19 2018

Merck’s Keytruda, Lilly’s Lartruvo available via CDF, merck pharma.#Merck #pharma

Merck’s Keytruda, Lilly’s Lartruvo available via CDF Patients with certain forms of lung cancer or sarcoma have now gained access to two new treatment options on the NHS in England after Merck s Keytruda and Eli Lilly s Lartruvo were added to the Cancer Drugs Fund. Keytruda (pembrolizumab) can be used to treat advanced lung cancer in people who have specific protein and genetic markers, potentially giving 1,400 extra patients access to the immunotherapy. The drug was recently recommended by NICE for routine by the NHS as a second line option for some patients with lung cancer; this new guidance …

Feb 19 2018

Eli Lilly CEO David Ricks expects Trump executive order on drug prices, lilly pharma.#Lilly #pharma

Eli Lilly CEO expects a Trump executive order on drug pricing this year Eli Lilly CEO David Ricks said he expects a presidential executive order targeting drug prices this year. div > div.group > p:first-child”> Ricks said on an earnings call Tuesday that he expects President Donald Trump to sign an order. Reports have indicated that a measure may be weeks away, perhaps after the Senate votes on health care reform. Trump bashed expensive prescription drugs on the campaign trail and has vowed to lower costs. Eli Lilly, which makes products to treat diabetes, cancer and other ailments, has raised …